Daewoong Pharmaceutical obtained the ISO 37001 international
certification through continuous efforts to diagnose and improve its
anti-bribery management system.
ISO 37001 is an international standard for anti-bribery
management systems established in October 2016 by the International
Organization for Standardization (ISO), with participation from 162
countries worldwide. It aims to systematically control and manage
the risk of bribery within organizations.
To obtain ISO 37001 certification,
Daewoong Pharmaceutical applied and analyzed international
standards related to fair trade laws, the Improper Solicitation and
Graft Act, and compliance practices within its business operations.
The company carried out enterprise-wide initiatives including CP
(Compliance Program) training for employees, risk assessments and
evaluations of bribery-related threats, goal management, and
internal audits. As a result of these comprehensive efforts,
Daewoong was awarded the ISO 37001 international certification in
December 2018.
Since then, Daewoong has consistently demonstrated the effectiveness
of its anti-bribery management system, successfully passing annual
surveillance audits as well as the second recertification audit in
December 2024, thereby continuing its commitment to ethical
and transparent business practices.
ISO 37001 Anti-Bribery Management System
The ISO 37001 Anti-Bribery Management System is a globally
recognized standard that defines the requirements applicable to
anti-bribery practices that may arise in any organizational
activity. It enables organizations to establish, implement,
maintain, and continuously improve an anti-bribery management
system, and is subject to third-party certification—making it a
trusted global benchmark for ethical operations.